Diagnosis and treatment specifcation for hepatitis B virus infection after organ transplantation (2019 dition)
-
摘要: 为了进一步规范实体器官移植（SOT）术后乙型肝炎病毒（HBV）感染的诊断和治疗，中华医学会器官移植学分会组织器官移植专家和感染病学专家，从流行病学、SOT术后HBV再感染或新发感染的危险因素、SOT术后HBV再感染或新发感染的诊断、SOT术后HBV再感染或新发感染的预防和治疗等方面，制订本规范，以帮助器官移植工作者规范和优化HBV感染的诊断和治疗。
-
关键词:
- 器官移植 /
- 乙型肝炎病毒 /
- 乙型肝炎表面抗原（HBsAg） /
- 乙型肝炎核心抗原（HBcAg） /
- 乙型肝炎核心抗体（抗-HBc） /
- 乙型肝炎表面抗体（抗-HBs） /
- 乙型肝炎e抗原（HBeAg） /
- 乙型肝炎e抗体（抗-HBe）
-
表 1 HBV标志物检测与结果分析
Table 1. HBV marker detection and result analysis
类型 HBV标志物 检测结果分析 HBsAg 抗-HBs HBeAg 抗-HBe 抗-HBc 抗-HBc IgM 1 + – + – – – 急性HBV感染，HBV复制活跃 2 + – + – + + 急性或慢性HBV感染，HBV复制活跃 3 + – – + + + 急性或慢性HBV感染，HBV复制减弱 4 + – – + + – HBV复制停止 5 – – – – + + HBV平静携带状态，或HBsAg/抗-HBs空白期 6 – – – – + – 既往HBV感染，未产生抗-HBs 7 – – – + + + 抗-HBs出现前阶段，HBV低度复制 8 – + – + + – HBV感染恢复阶段 9 + + + – + + 不同亚型（变异型）HBV再感染 10 – + – – – – 疫苗接种后获得性免疫 11 – + – – + – 自然感染引起的免疫 
下载: 导出CSV
-
[1] WONG MCS, HUANG JLW, GEORGE J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(1):57-73. DOI: 10.1038/s41575-018-0055-0. [2] ZHANG Y, ZHANG H, ELIZABETH A, et al. Epidemiology of hepatitis B and associated liver diseases in China[J]. Chin Med Sci J, 2013, 27(4):243-248. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=cmsj-e201204009 [3] LIANG X, BI S, YANG W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47):6550-6557. DOI: 10.1016/j.vaccine.2009.08.048. [4] CUI F, SHEN L, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5):765-772. DOI: 10.3201/eid2305.161477. [5] 崔富强.中国人群乙型病毒性肝炎血清流行病学调查——乙型肝炎疫苗接种降低乙型肝炎病毒感染率[J].中国疫苗和免疫, 2010, 16(4):341, 353. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjhmy201004013CUI FQ. Epidemiological serosurvey of hepatis B in China——declining HBV prevalence due to hepatitis B vaccination[J]. Chin J Vacc Immun, 2010, 16(4):341, 353. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjhmy201004013 [6] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志, 2015, 31(12):1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.Branch of Hepatology of Chinese Medical Association, Branch of Infectious Diseases of Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12):1941-1960.DOI: 10.3969/j.issn.1001-5256.2015.12.002. [7] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):383-403. DOI: 10.1016/S2468-1253(18)30056-6. [8] 中华医学会器官移植学分会, 中华医学会肝病学分会.中国肝移植乙型肝炎防治指南(2016版)[J].临床肝胆病杂志, 2017, 33(2):213-220.DOI: 10.3969/j.issn.1001-5256.2017.02.002.Branch of Organ Transplantation of Chinese Medical Association, Branch of Hepatology of Chinese Medical Association. The practice guideline on prophylaxis and treatment of hepatitis B for liver transplantation in China (2016 edition) [J]. J Clin Hepatol, 2017, 33(2):213-220. DOI: 10.3969/j.issn.1001-5256.2017.02.002. [9] SAMUEL D, MULLER R, ALEXANDER G, et al. Liver transplantation in European patients with the hepatitis B surface antigen[J]. N Engl J Med, 1993, 329(25):1842-1847. doi: 10.1056/NEJM199312163292503 [10] 齐俊英, 谢复东, 郭林生, 等.维持性血液透析及肾移植患者乙型及丙型肝炎病毒感染调查[J].中华医院感染学杂志, 2003, 13(9):805-807.DOI: 10.3321/j.issn:1005-4529.2003.09.002.QI JY, XIE FD, GUO LS, et al. The status of hepatitis B virus and hepatitis C virus infection in patients receiving maintenance hemodialysis and kidney transplantation[J]. Chin J Nosocomiol, 2003, 13(9):805-807. DOI: 10.3321/j.issn:1005-4529.2003.09.002. [11] 孙启全, 王金泉.乙型肝炎病毒感染对肾移植患者预后的影响[J].肾脏病与透析肾移植杂志, 2004, 13(3):283-287.DOI: 10.3969/j.issn.1006-298X.2004.03.021.SUN QQ, WANG JQ. Effects of hepatitis B virus infection on the prognosis of renal transplant patients[J]. Chin J Nephr Dial Transplant, 2004, 13(3):283-287. DOI: 10.3969/j.issn.1006-298X.2004.03.021. [12] 袁伟升, 宫琳, 刘鹏, 等.拉米夫定联合小剂量乙肝免疫球蛋白预防肝移植术后HBV再感染的临床分析[J].中国普外基础与临床杂志, 2015, 22(4):451-454. DOI: 10.7507/1007-9424.20150119.YUAN WS, GONG L, LIU P, et al. Clinical analysis of lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV reinfection after liver transplantation[J]. Chin J Bas Clin Gen Surg, 2015, 22(4):451-454.DOI: 10.7507/1007-9424.20150119. [13] 沈中阳, 朱志军, 邓永林, 等.小剂量HBIg联合核苷类似物预防肝移植术后乙肝复发1506例回顾性分析[J].中华肝胆外科杂志, 2011, 17(5):364-366.DOI: 10.3760/cma.j.issn.1007-8118.2011.05.005.SHEN ZY, ZHU ZJ, DENG YL, et al. Combination of low-dose HBIg and nucleoside analogues to prevent recurrent hepatitis B virus after liver transplantation: a retrospective analysis of 1506 cases[J]. Chin J Hepatobil Surg, 2011, 17(5):364-366. DOI: 10.3760/cma.j.issn.1007-8118.2011.05.005. [14] SUZUKI F, TSUBOTA A, ARASE Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan[J]. Intervirology, 2003, 46(3):182-189. doi: 10.1159/000071460 [15] 张闻辉, 邓永林, 郑虹, 等.肝移植术后新发乙型肝炎病毒感染的临床分析[J].中华器官移植杂志, 2012, 33(5):295-298.DOI: 10.3760/cma.j.issn.0254-1785.2012.05.010.ZHANG WH, DENG YL, ZHENG H, et al. Clinical analysis of de novo hepatitis B virus infection after liver transplantation[J]. Chin J Organ Transplant, 2012, 33(5):295-298.DOI: 10.3760/cma.j.issn.0254-1785.2012.05.010. [16] MACCONMARA MP, VACHHARAJANI N, WELLEN JR, et al. Utilization of hepatitis B core antibody-positive donor liver grafts[J]. HPB (Oxford), 2012, 14(1):42-48. DOI: 10.1111/j.1477-2574.2011.00399.x. [17] AVELINO-SILVA VI, D'ALBUQUERQUE LA, BONAZZI PR, et al. Liver transplant from anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? a systematic review of the literature[J]. Clin Transplant, 2010, 24(6):735-746. DOI: 10.1111/j.1399-0012.2010.01254.x. [18] MAGIORKINIS E, PARASKEVIS D, PAVLOPOULOU ID, et al. Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: a case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature[J]. Transpl Infect Dis, 2013, 15(4):393-399. DOI: 10.1111/tid.12094. [19] 鞠卫强, 何晓顺, 王东平, 等.乙型肝炎表面抗原阳性供肝在肝移植中的应用[J].中华肝脏病杂志, 2012, 20(1):14-16. DOI: 10.3760/cma.j.issn.1007-3418.2012.01.006.JU WQ, HE XS, WANG DP, et al. A study of the efficacy and safety of using hepatitis B surface antigen-positive donors for liver transplantation[J]. Chin J Hepatol, 2012, 20(1):14-16.DOI: 10.3760/cma.j.issn.1007-3418.2012.01.006. [20] LOGGI E, MICCO L, ERCOLANI G, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool[J]. J Hepatol, 2012, 56(3):579-585. DOI: 10.1016/j.jhep.2011.09.016. [21] YU S, YU J, ZHANG W, et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation[J]. J Hepatol, 2014, 61(4):809-815. DOI: 10.1016/j.jhep.2014.05.003. [22] 姜涛, 卢实春, 赖威, 等.HBsAg阳性供肝和HBcAb阳性供肝在肝移植中的应用[J].中华器官移植杂志, 2012, 33(4):200-204.DOI: 10.3760/cma.j.issn.0254-1785.2012.04.003.JIANG T, LU SC, LAI W, et al. Utilization of liver grafts from hepatitis B surface antigen positive or anti-hepatitis B core positive donors[J]. Chin J Organ Transplant, 2012, 33(4):200-204.DOI: 10.3760/cma.j.issn.0254-1785.2012.04.003. [23] CHOLONGITAS E, PAPATHEODORIDIS GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review[J]. Am J Transplant, 2013, 13(2):353-362. DOI: 10.1111/j.1600-6143.2012.04315.x. [24] FUNG J, WONG T, CHOK K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatology, 2017, 66(4):1036-1044. DOI: 10.1002/hep.29191. -
下载: 
点击查看大图
表(1)
计量
- 文章访问数: 234
- HTML全文浏览量: 80
- PDF下载量: 84
- 被引次数: 0
